5-Chloro-2-(2′-((dimethylamino)methyl)-4′-iodophenylthio)benzenamine: a new serotonin transporter ligand

Nuclear Medicine and Biology

Volumn 34, Issue 2, 2007, Pages 129-139

  Oya, Shunichi ^a   Choi, Seok Rye ^a   Kung, Mei Ping ^a   Kung, Hank F ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,5,6,10B HEXAHYDRO 6 (4 METHYLTHIOPHENYL)PYRROLO[2,1 A]ISOQUINOLINE; 2 [2' [(DIMETHYLAMINO)METHYL] 4' METHOXYPHENYLTHIO] 5 IODOBENZENAMINE; 2 [2' [(DIMETHYLAMINO)METHYL] 4' METHOXYPHENYLTHIO] 5 IODOBENZENAMINE I 125; 2 [4' BROMO 2' [(DIMETHYLAMINO)METHYL]PHENYLTHIO] 5 CHLOROBENZENAMINE; 2 [[2 [(DIMETHYLAMINO)METHYL]PHENYL]THIO] 5 IODOPHENYLAMINE I 125; 4' (2 AMINO 4 BROMOPHENYLTHIO) 3' [(DIMETHYLAMINO)METHYL]PHENOL; 5 BROMO 2 [4' BROMO 2' [(DIMETHYLAMINO)METHYL]PHENYLTHIO]BENZENAMINE; 5 BROMO 2' [2 [(DIMETHYLAMINO)METHYL] 4' METHOXYPHENYLTHIO]BENZENAMINE; 5 CHLORO 2 [2' [(DIMETHYLAMINO)METHYL] 4' IODOPHENYLTHIO]BENZENAMINE; 5 CHLORO 2 [2' [(DIMETHYLAMINO)METHYL] 4' IODOPHENYLTHIO]BENZENAMINE I 125; BENZENE DERIVATIVE; DOPAMINE TRANSPORTER; ESCITALOPRAM; IODINE DERIVATIVE; NISOXETINE; NORADRENALIN TRANSPORTER; SEROTONIN TRANSPORTER; TRACER; UNCLASSIFIED DRUG; VANOXERINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; CEREBELLUM; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG RETENTION; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG UPTAKE; EX VIVO STUDY; HYPOTHALAMUS; ISOTOPE LABELING; MALE; NEUROIMAGING; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANILINE COMPOUNDS; ANIMALS; BRAIN; IODINE RADIOISOTOPES; MALE; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; RATS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SULFIDES; TISSUE DISTRIBUTION;

EID: 33846925838     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.12.002     Document Type: Article

References (51)

1. Owens M.J., and Nemeroff C.B. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40 (1994) 288-295
2. Frazer A. Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. J Clin Psychiatry 62 (2001) 16-23
3. Frazer A. Antidepressants. J Clin Psychiatry 6 (1997) 9-25
4. Owens M.J. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry 4 (2004) 5-10
5. Holtzheimer III P.E., and Nemeroff C.B. Advances in the treatment of depression. NeuroRx 3 (2006) 42-56
6. Nemeroff C.B. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatr Res (2006)
7. White K.J., Walline C.C., and Barker E.L. Serotonin transporters: implications for antidepressant drug development. AAPS J 7 (2005) E421-E433
8. Cavanagh J., Patterson J., Pimlott S., Dewar D., Eersels J., Dempsey M.F., et al. Serotonin transporter residual availability during long-term antidepressant therapy does not differentiate responder and nonresponder unipolar patients. Biol Psychiatry (2005)
9. 123I]IDAM as a novel single-photon emission tomography tracer for serotonin transporters. Eur J Nucl Med 26 (1999) 844-853
10. Choi S.R., Hou C., Oya S., Mu M., Kung M.P., Siciliano M., et al. Selective in vitro and in vivo binding of [(125)I]ADAM to serotonin transporters in rat brain. Synapse 38 (2000) 403-412
11. Kung H.F., Newman S., Choi S.R., Oya S., Hou C., Zhuang Z.P., et al. 2-(2-(Dimethylaminomethyl)phenoxy)-5-iodophenylamine: an improved serotonin transporter imaging agent. J Med Chem 47 (2004) 5258-5264
12. 11C-labeled 2-(phenylthio)araalkylamines. J Med Chem 43 (2000) 3103-3110
13. Parsey R.V., Kent J.M., Oquendo M.A., Richards M.C., Pratap M., Cooper T.B., et al. Acute occupancy of brain serotonin transporter by sertraline as measured by [(11)C]DASB and positron emission tomography. Biol Psychiatry (2005)
14. Giovacchini G., Lang L., Ma Y., Herscovitch P., Eckelman W.C., and Carson R.E. Differential effects of paroxetine on raphe and cortical 5-HT1A binding: a PET study in monkeys. Neuroimage 28 (2005) 238-248
15. Buchert R., Schulze O., Wilke F., Berding G., Thomasius R., Petersen K., et al. Is correction for age necessary in SPECT or PET of the central serotonin transporter in young, healthy adults?. J Nucl Med 47 (2006) 38-42
16. Buchert R., Thomasius R., Petersen K., Wilke F., Obrocki J., Nebeling B., et al. Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users. Eur J Nucl Med Mol Imaging 33 (2006) 188-199
17. Brust P., Hesse S., Mueller U., and Szabo Z. Neuroimaging of the serotonin transporter: possibilities and pitfalls. Current Psychiatry Reviews 2 (2006) 111-149
18. 11C]DASB and positron emission tomography. Biol Psychiatry 59 (2006) 821-828
19. 123I[ADAM] in healthy controls: a selective SERT radioligand. Int J Neuropsychopharmacol (2006) 1-8
20. Klein N., Sacher J., Geiss-Granadia T., Attarbaschi T., Mossaheb N., Lanzenberger R., et al. In vivo imaging of serotonin transporter occupancy by means of SPECT and [(123)I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology (Berl) 188 (2006) 263-272
21. Booij J., and de Win M.M. Brain kinetics of the new selective serotonin transporter tracer [(123)I]ADAM in healthy young adults. Nucl Med Biol 33 (2006) 185-191
22. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. J Nucl Med 46 (2005) 973-977
23. 123I]ADAM: a SPECT validation study. Eur J Nucl Med Mol Imaging 32 (2005) 1329-1336
24. Guilloteau D., and Chalon S. PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders. Curr Pharm Des 11 (2005) 3237-3245
25. Mathis C.A., Biegon A., Taylor S.E., Enas J.D., and Hanrahan S.M. [I-125]5-Iodo-6-nitro-2-piperazinylquinoline: a potent and selective ligand for the serotonin uptake complex. Eur J Pharmacol 210 (1992) 103-104
26. Jagust W.J., Eberling J.L., Biegon A., Taylor S.E., VanBrocklin H.F., Jordan S., et al. Iodine-123-5-iodo-6-nitroquipazine: SPECT radiotracer to image the serotonin transporter. J Nucl Med 37 (1996) 1207-1214
27. 125I]5-Iodo-6-nitroquipazine: a potent and selective ligand for the 5-hydroxytryptamine uptake complex I in vitro studies. Brain Res 619 (1993) 229-235
28. Stehouwer J.S., Plisson C., Jarkas N., Zeng F., Voll R.J., Williams L., et al. Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 (N-fluoroalkyl) labeled 2beta-carbomethoxy-3beta-(4′-(3-furyl)phenyl)tropanes and -nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. J Med Chem 48 (2005) 7080-7083
29. 123I]-β-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biol Psychiatry 47 (2000) 482-489
30. Bergstrom K.A., Halldin C., Hall H., Lundkvist C., Ginovart N., Swahn C.G., et al. In vitro and in vivo characterisation of nor-beta-CIT: a potential radioligand for visualisation of the serotonin transporter in the brain. Eur J Nucl Med 24 (1997) 596-601
31. 18F]fluoromethyl-(+)-McN5652, a PET tracer for the serotonin transporter: evaluation in rats. Synapse 47 (2003) 45-53
32. 18F]fluoromethyl analogue of (+)-McN5652. Synthesis and applications of isotopically labelled compounds. Proceedings of the International Symposium, 7th, Dresden, Germany, June 18-22, 2000 (2001) 377-379
33. Suehiro M., Musachio J.L., Dannals R.F., Mathews W.B., Ravert H.T., Scheffel U., et al. An improved method for the synthesis of radiolabeled McN5652 via thioester precursors. Nucl Med Biol 22 (1995) 543-545
34. Maryanoff E.M., Vaught J.L., Shank R.P., McComsey D.F., Costanzo M.J., and Nortey S.O. Pyrroloisoquinolines antidepressants: 3. A focus on serotonin. J Med Chem 33 (1990) 2793-2797
35. Maryanoff B.E., McComsey D.F., Gardocki J.F., Shank R.P., Costanzo M.J., Nortey S.O., et al. Pyrroloisoquinoline antidepressants: 2. In-depth exploration of structure-activity relationships. J Med Chem 30 (1987) 1433-1454 [published erratum appears in J Med Chem 1988 Jan; 31(1):276]
36. Vercouillie J., Mavel S., Galineau L., Ragusa T., Innis R., Kassiou M., et al. Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands. Bioorg Med Chem Lett 16 (2006) 1297-1300
37. Zhang S., Zhen J., Reith M.E., and Dutta A.K. Design, synthesis, and preliminary SAR study of 3- and 6-side-chain-extended tetrahydro-pyran analogues of cis- and trans-(6-benzhydryl-tetrahydropyran-3-yl)-benzylamine. Bioorg Med Chem (2006)
38. 11C]SMe-ADAM, an imaging agent for the brain serotonin transporter: synthesis, pharmacological characterization and microPET studies in rats. Nucl Med Biol 33 (2006) 53-63
39. Jarkas N., Votaw J.R., Voll R.J., Williams L., Camp V.M., Owens M.J., et al. Carbon-11 HOMADAM: a novel PET radiotracer for imaging serotonin transporters. Nucl Med Biol 32 (2005) 211-224
40. Jarkas N., McConathy J., Votaw J.R., Voll R.J., Malveaux E., Camp V.M., et al. Synthesis and characterization of EADAM: a selective radioligand for mapping the brain serotonin transporters by positron emission tomography. Nucl Med Biol 32 (2005) 75-86
41. Huang Y., Bae S.A., Zhu Z., Guo N., Roth B.L., and Laruelle M. Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents. J Med Chem 48 (2005) 2559-2570
42. 123I] IDAM, 5-iodo-2-((2-((dimethylamino)methyl)phenyl)thio)benzyl alcohol. J Med Chem 42 (1999) 333-335
43. Oya S., Choi S.R., Hou C., Mu M., Kung M.P., Acton P.D., et al. 2-((2-((Dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. Nucl Med Biol 27 (2000) 249-254
44. 18F]ACF (2-[(2-amino-4-chloro-5-fluorophenyl)thio]-N,N-dimethyl-benzenmethanamine). J Med Chem 45 (2002) 4716-4723
45. Gu H., Wall S.C., and Rudnick G. Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem 269 (1994) 7124-7130
46. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1986), Academic Press, New York
47. 3H]paroxetine. Neuroscience 27 (1988) 473-496
48. 125I]5-Iodo-6-nitroquipazine: a potent and selective ligand for the 5-hydroxytryptamine uptake complex II in vivo studies in rats. Brain Res 619 (1993) 236-246
49. 3H-paroxetine-labeled serotonin uptake sites in rat brain. Synapse 1 (1987) 488-496
50. 125I]iodo-nisoxetine to norepinephrine transporters in the brain. Nucl Med Biol 31 (2004) 533-541
51. Kung M.-P., Essman W.D., Frederick D., Meegalla S., Goodman M., Mu M., et al. IPT: a novel iodinated ligand for the CNS dopamine transporter. Synapse 20 (1995) 316-324